

2012 Ballot - Society for Thermal Medicine

I. Vice President-Elect Candidates



Dr. Michael William Graner, PhD
University of Colorado at Denver
Department of Neurosurgery
Denver, Colorado

Current Research Interests: Tumor stress, heat shock protein immunotherapy, exosome biology

Education:

University of Illinois
Illinois College

Degree Earned PhD
BA

Field of Study: Biochemistry
English, Biology

Vision Statement:

My goal for contributions to the Society would be to maintain and expand interest in utilizing tumor stress responses as points of therapeutic intervention, particularly in regards to immunotherapy. The breadth of the Society's expertise and in particular the talents within it to turn complex protocols and procedures into a viable clinical moieties needs to be further impressed upon practicing clinicians. I also want to increase membership in our region, and would seek additional sources of funding for the Society.

Current Work Position : Associate Professor, University of Colorado Anschutz Medical Campus (UC Denver), Department of Neurosurgery

Previous Thermal Medicine related work experiences

Associate Research Professor, Duke University (Preston Robert Tisch Brain Tumor Center)

--developing targeted therapies to cell surface heat shock proteins; "discovered" exosomes from brain tumors

Assistant Research Professor/Scientist/Post-doc, University of Arizona, Pediatrics

--co-inventor of a heat-shock protein-based vaccine that is currently part of an upcoming clinical trial at the University of Colorado Denver/Anschutz Medical Campus.



Dr. Robert Griffin, PhD
University of Arkansas for Medical Sciences
Dept of Radiation Oncology
Little Rock, Arkansas

Current Research Interests: Biology and physiology of thermal therapy; Molecular and physiological mechanisms of radiation and thermal sensitization; Modulation of tumor blood flow, angiogenesis and oxygenation; Oxygen partial pressure as predictor of cancer treatment response

Vision Statement:

My vision for the STM is to foster scientific investigators looking at any aspect of thermal medicine to maintain a relevant knowledge base from which clinicians and translational researchers can support clinical trials incorporating thermal, radiation or drug therapy. Our society is notable due to its basic science and engineering/physics foundation and work to understand the mechanisms of action for a full range of thermal medicine applications. It is therefore valuable to many of the rapidly expanding areas of device development and interventional approaches using thermal therapy at an increasing frequency. In this way, we need to vigorously promote and expand and the ideas and logic behind thermal therapy basic

and applied science into the greater oncology community whenever our society has the chance to do so. These activities will open new channels for publication and grant support and, most important of all, exploit the powerful biological and physical characteristics of thermal stress for the benefit of the patient. In addition, I believe that we need to remain 'connected' to the members of various study sections that review and fund thermal therapy-related research. As an officer of the society I would strive to make sure individuals that are on these review panels are invited and encouraged to participate in the society in any and every way possible. These activities are important for furthering the overall goals and interests of the members of the society and helping to maintain our most valuable aspect as a society- a fundable and strong basic science foundation that naturally supports improved clinical implementation of thermal medicine.

Current Position: Associate Professor, Department of Radiation Oncology, University of Arkansas for Medical Sciences Little Rock, AR

Education:

BA, St. Olaf College
PhD Biophysical Sciences, University of Minnesota, 1998

Work Experience:

Associate Professor, December 2006-present. Dept. of Radiation Oncology/Breast Cancer research and development, University of Arkansas for Medical Sciences, Little Rock, AR.

Assistant Professor of Radiobiology, July 2000-2006. Dept. of Therapeutic Radiology-Radiation Oncology, University of Minnesota Medical School.

Postdoctoral Associate, April 1998-July 2000. Dept. of Therapeutic Radiology-Radiation Oncology, University of Minnesota Medical School, Minneapolis, MN.

Awards and Honors:

Travel Awards: Radiation Research Society/North American Hyperthermia Society annual meetings, 1995 and 1996, International Congress of Radiation Research, 2003.

Councilor in biology, STM 2005-2008

II. Secretary/Treasurer-Elect Candidates



Dr. Erik N.K. Cressman, MD, PhD
University of Minnesota
Department of Radiology
Minneapolis, Minnesota

Current Research Interests:

Thermochemical ablation, thermal denaturation and monitoring, HIFU, liver and kidney cancers

Education:

University	Degree Earned	Field of Study
University of Utah	PhD	Organic Chemistry
Indiana University	MD	Medicine
Indiana University	Residency	Diagnostic Radiology
Indiana University	Fellowship	Interventional Radiology

Vision Statement:

The reality of hyperthermia in its many forms is that it works. As members of the society, we all know this. Getting patients and the broader medical and insurance communities to embrace it, however, is a significant challenge. I believe that the STM should expand by raising its profile across the board. I would like to increase the interaction with those using the higher temperature thermal therapies such as physicians in surgical oncology and interventional radiology, in addition to the milder hyperthermia specialties. Beyond that, there are opportunities for education of primary care physicians, graduate students, and even (or especially) medical students. As one who sees cancer patients on a regular basis, deals with other clinicians, and one who can leverage my involvement in the Society of Interventional Radiology, I can help to build those bridges and establish new relationships.

Current Work Position:

Assistant Professor, University of Minnesota

Thermal Medicine Related National / International Awards, Honors & Recognition:

Gary Becker Young Investigator Award, SIR Foundation
Ernest J. Ring Faculty Development Award, SIR Foundation



Dr. Sunil Krishnan
MD Anderson Cancer Center
Department of Radiation Oncology
Houston, Texas

Current Research Interests:

Nanoparticle-mediated hyperthermia – applications, mechanisms, modeling, and monitoring.

Vision Statement:

Despite overwhelming preclinical and clinical evidence of its efficacy as an adjunct to radiation therapy and chemotherapy, hyperthermia is clinically underutilized in oncologic practice. Among the many reasons for this are (a) the invasive means of generating and maintaining hyperthermia, (b) the logistical challenge of sequencing it closely with radiotherapy and/or chemotherapy, (c) the lack of readily deployable means of real-time temperature monitoring or dosimetry; and (d) the lack of uniform description of dose and time attributes of hyperthermia in many clinical trials. In recent years, advances in our technical capabilities and our understanding of the mechanisms of hyperthermic radio- and chemo- sensitization have resulted in a greater ability to address each of these challenges. It is now incumbent upon us to translate these advances to the clinic. Specific issues that are worth championing during this transition are (a) dissemination of this knowledge in appropriate clinical venues and fora; (b) design and initiation of collaborative clinical trials; (c) increasing industry, academia, government and private funding of and involvement in such trials nationally and internationally; (d) bringing back information gleaned from the clinic to the laboratory to refine treatment paradigms; and (e) recruiting a new cadre of clinicians and researchers to the field. My vision for the STM is to serve as a focal point for coordinated efforts on all of these fronts. As a governing body member of the society, my contribution would be to serve as a passionate advocate for and an active participant in these endeavors.

Current Position:

Associate Professor, Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030

Education:

Medicine – Christian Medical College, Vellore, India 1993
Internal Medicine residency – Penn State Geisinger Medical Center, Danville, PA 2000
Radiation Oncology residency, Mayo Clinic, Rochester, MN 2004

Work Experience:

Tutor, Biochemistry Department, Christian Medical College, Vellore, India 1995

Assistant Professor, Radiation Oncology, MD Anderson Cancer Center, Houston, TX 2004-2009

Associate Professor, Radiation Oncology, MD Anderson Cancer Center, Houston, TX 2009-present

Awards and Honors:

- Indian Council for Medical Research National Junior Research Scholarship, India, 1992
- Christian Medical College Research Prize, India 1993
- J. N. Tata Endowment Scholarship, India, 1996
- AMA Foundation Leadership Award, 2002
- Robert D. and Alma Moreton Fellowship, Mayo Clinic, Rochester, 2002
- Mayo Brother's Distinguished Fellowship Award, Mayo Clinic Graduate School of Medicine in Rochester/Scottsdale/Jacksonville, 2002
- Roentgen Resident/Fellow Research Award, Radiological Society of North America, 2003
- Radiation Therapy Oncology Group Travel Award 2003
- American Society for Therapeutic and Radiation Oncology Translational Research Symposium Travel Grant 2005

III. Councilor Candidates – Biological & Chemical Sciences

Dr. Darin Y. Furgeson, PhD
University Of Utah
Dept of Pharmaceutics
Salt Lake City, Utah

Current Research Interests:

Primary research interests are in interventional oncology, targeted drug delivery, siRNA gene therapy across the blood brain barrier for neurodegenerative disorders, nanotoxicology, and pediatric environmental health.

Education:

1998 B.Sc. in Chemical Engineering

University of Utah

2000 Masters in Chemical Engineering

University of Utah

2003 Ph.D. in Pharmaceutics and Pharmaceutical Chemistry

University of Utah

Vision Statement: - none provided

Current Work Position : Assistant Professor of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah.

Additional duties include:

Adjunct Assistant Professor, Bioengineering, University of Utah

Adjunct Assistant Professor, Pediatrics, University of Utah

Adjunct Assistant Professor, Chemical Engineering, University of Utah

Adjunct Assistant Professor, Pharmacology And Toxicology, University of Utah

Assistant Professor, Pharmaceutical Chemistry, University of Utah

Previous Thermal Medicine related work experiences:

Has numerous collaborations with the Departments of Interventional Oncology, Surgical

Oncology, Electrical Engineering, Bioengineering, Pediatric Pathology, Pediatrics, and the Huntsman Cancer Institute in addition to the Nanotechnology Characterization Laboratory (NCL), and NIH. Current disease targets include: liver cancer, breast cancer, melanoma, amyotrophic lateral sclerosis (ALS; Lou Gehrig's Disease), and brain tumors.



Dr. Randy Burd, PhD
University of Arizona Cancer Center
Department of Nutritional Sciences
Tucson, Arizona

Current Research Interests:

Current research interests in our laboratory focus on improving tumor radiation response through the use of *biological response modifiers* that alter tumor cell function, metabolism, cytokine stimulation and prostaglandin production, and affect aspects of tumor development, growth and treatment response. These include pharmaceutical drugs that are designed to specifically target tumors, bioactive nutritional components such as bioflavonoids, and compounds that regulate tumor glucose metabolism.

Education:

Ph.D., Molecular and Cellular Biophysics, University at Buffalo/Roswell Park Cancer Institute, 1998
B.A., Biological Sciences, University College at Buffalo, 1994

Vision Statement: - none provided

Current Work Position:

Assistant Professor at the University of Arizona Cancer Center, in Tucson, AZ.

IV. Councilor Candidates – Clinical & Medical Sciences



Dr. Muneeb Ahmed
Beth Israel Deaconess Medical Center
Department of Interventional Radiology
Boston, Massachusetts

Current Research Interests:

Research interests are focused on using image-guidance to perform minimally invasive and directed therapies to treat localized tumors. This includes using percutaneous tumor ablation (using radiofrequency or cryoablation) in combination with systemic targeted chemotherapy, and administered targeted therapy through direct intra-arterial injection (such as chemoembolization).

Education:

- The Aga Khan University Medical College, Pakistan
- NCI Research Fellow in Cancer Radiology, Beth Israel Deaconess Medical Center
- Internship, Metrowest Medical Center/Harvard Medical School Affiliate

- Residency in Diagnostic Radiology, Beth Israel Deaconess Medical Center/Harvard Medical School
- Chief Resident, Radiology Residency Program, Beth Israel Deaconess Medical Center
- Fellowship in Vascular and Interventional Radiology, The Johns Hopkins School of Medicine

Vision Statement: - none provided

Current Work Position :

- Staff Radiologist, Interventional Radiology, Beth Israel Deaconess Medical Center
- Assistant Professor of Radiology, Harvard Medical School

Previous Thermal Medicine related work experiences:



Prof. Paul Jack Hoopes, DVM, PhD
Dartmouth Medical School
Lebanon, New Hampshire

Current Research Interests:

Radiation therapy, biology and pathology
 Hyperthermia therapy, biology and pathology
 Veterinary and cancer pathology
 Nanotechnology - all areas related to cancer diagnosis and therapy but especially with respect to iron oxide nanoparticle (magnetic nanoparticle) hyperthermia cancer treatment

Education:

University	Degree Earned		Field of Study
Oklahoma University, Norman, OK		1969-71	Liberal Arts
Oklahoma State University, Stillwater, OK	D.V.M.	1972-76	Veterinary Medicine
NIH (FAES) Graduate School, Bethesda, MD		1977-78	Pathology
Colorado State University, Fort Collins, CO	Ph.D.	1980-84	Pathology/Rad Biology
Colorado State University, Fort Collins, CO	Fellowship	1984-86	Radiation Pathology
North Carolina State University, Raleigh, NC	Fellowship	1986-1988	Radiation /Oncology
Duke University Medical Center, Durham, NC			Cancer Therapeutics
Duke University			

STM Vision Statement;

I have been associated directly with radiation and hyperthermia cancer biology and treatment for my entire career, first with Ed Gillette (PhD mentor, Colorado State University) and then with Mark Dewhirst (Duke University) and Don Thrall (North Carolina State University). Upon Moving to Dartmouth, I was closely associated with John Strohhahn, Keith Paulsen, Stuart Trembly, Evan Douple, Thomas Ryan, David Roberts and other hyperthermia biology, engineering and clinical experts. Dartmouth was very well supported by NIH-hyperthermia based grants and funds until hyperthermia hit a roadblock in the late 1990 and early 2000's. It is my personal feeling that hyperthermia cancer therapy was, at some level, unfairly critiqued and categorized by unfavorable early clinical trials that were run by investigators, some of whom did not have the engineering, thermometry, biology and/or clinical support and experience to conduct the trials at an appropriate level. Many of these trials were not favorable for hyperthermia. We, perhaps, would have had different outcomes with more knowledge and support.

Finding the right technique and situation for hyperthermia cancer therapy is challenging. However, as we all know, heat can be highly

effective if used appropriately and in the correct setting. The mission of our society is too improve the techniques and opportunities with better modeling, engineering, biology and clinical/thermal dose understanding. Many of these opportunities are just now emerging.

We, at Dartmouth, are heavily engaged in one of the new hyperthermia-based cancer treatment technologies I alluded to above: iron oxide/magnetic nanoparticle (NP) hyperthermia cancer treatment. We have shown our therapy is safe and can be very effective in rodent tumor models. However, we cannot directly measure nanoparticle-based intracellular thermal dose or image the NP biodistribution in real-time with conventional imaging. That said, the ability to tag and localize the NPs to individual cancer cells with cancer antibodies and use new imaging techniques such as MRI-SWIFT offer great promise. There are now many other hyperthermia, ablation and cryotherapy technologies (HIFU, etc) which offer great promise. With the new translational mentality, we have to find ways to move to into the clinical setting at reasonable pace (involving more clinicians – early in the research, so that they have time to understand and influence), but not before a technology is ready. I feel we should also focus on combination therapies which involve temperature alteration.

I have been associated directly with radiation and hyperthermia cancer biology and treatment for my entire career; first with Ed Gillette (PhD mentor, Colorado State University), then with Mark Dewhirst and Don Thrall (Duke University, North Carolina State University respectively). Upon Moving to Dartmouth (current institution and home) I was closely associated with John Strohhahn, Keith Paulsen, Stuart Trembly, Evan Douple, Thomas Ryan , David Roberts and other hyperthermia biology, engineering and clinical experts. Dartmouth was very well supported by NIH-hyperthermia based grants and funds until hyperthermia hit a road block in the late 1990 and early 2000's. It is my personal feeling that hyperthermia cancer therapy was, at some level, unfairly critiqued and categorized by unfavorable early clinical trials that were run by investigators some of whom did not have the engineering, thermometry, biology and /or clinical support (and maybe sometimes the knowledge and /or experience) to conduct the trials at an appropriate level. Many of these trials were not favorable for hyperthermia. Would some have had a different outcome with more knowledge and support (even at that

Finding the right technique and situation for hyperthermia cancer therapy is challenge, however it can be highly effective if used appropriately in the correct setting. The mission is too improve the techniques and opportunities with better modeling, engineering , biology and clinical / thermal dose understanding. Many such opportunities are just now emerging.

We, at Dartmouth, are heavily engaged in one of the new hyperthermia base cancer treatment technologies I alluded to above; iron oxide/magnetic nanoparticle hyperthermia cancer treatment. We have shown our therapy is safe and can be very effective in rodent tumor models. However we can not directly measure nanoparticle- based intracellular heating /thermal dose or see the NPs (tumor location/amount/biodistribution), in real-time with conventional imaging. That said the ability to tag and localize the NPs to individual cancer cells with cancer antibodies and use new imaging techniques such as MRI-SWIFT offer great promise. There are now many other other hyperthermia technologies (HFU etc) which offer great promise. With the new translational mentality, we have to find ways to move to into the clinical setting at reasonable pace, but not before a technology is ready. I feel we should also focus on combination therapies which involve hyperthermia .

Current Work Position: Professor , Dartmouth College (duties, positions below)

1992 - pres Director, Irradiation Shared Resource, Norris Cotton Cancer Center, DMS/DHMC
1996 - pres Director, Surgery, Radiation Oncology and Bioengineering Research Laboratories, NCCC, DMS, DHMC, Thayer School of Engineering
2002 - 2010 Chairman, Radiation Safety Committee, Dartmouth College (current member)
2005 - pres Vice Chairman, Dartmouth College Institutional Animal Care and Use Committee (IACUC)
2005 - pres Director, NCCC Cancer Nanotechnology Working Group
2008 - pres **Professor of Surgery and Radiation Oncology (tenure), DMS/NCCC**
Adjunct Prof Biomedical Engineering, Thayer Engineering School, DC
2009 – pres Director, Center for Comparative Medicine (Animal Care and Use Program), Dartmouth College
2010 – pres Co-Director, Small Animal Imaging Shared Resource, Norris Cotton Cancer Center, DMS /DHMC

Previous Thermal Medicine related work experiences

1976 - 1977 Intern, Meriweather Veterinary Hospital, Miller, SD
1977 - 1979 Intern, Exotic Animal Med and Pathology, National Zoological Park, Washington, DC
1979 – 1982 Resident, Pathology, Colorado State Univ, College of Vet Med , Fort Collins, CO
1981 - 1984 Graduate Student, Pathology/Radiation Biology, Colo State Univ., Fort Collins, CO
1984 - 1985 Post-Doctoral Fellow, Pathology/Rad Oncology, Colo State Univ., Fort Collins, CO

1985 - 1988 Post Doctoral Fellow and Pathologist (NC Animal Cancer Treatment Program), School of Veterinary Med, NC State Univ., Raleigh, NC & Duke Univ. Med Ctr., Durham, NC
1988 – Dartmouth College (see below)

General History: I am a veterinarian with specialty training in veterinary pathology (residency). My academic graduate training is in radiation and hyperthermia biology / radiation oncology (PhD / post-doc), focused on the pathogenesis and sparing of radiation normal tissue injury and experimental cancer therapeutics. Additional post-doctoral training in experimental radiation and hyperthermia cancer therapeutics was conducted at the North Carolina State University School of Veterinary Medicine (Donald Thrall) and Duke University Medical Center / Radiation Oncology (Mark Dewhirst et al). Virtually all of my post-veterinary and graduate training was performed in an NIH-PPG funded, translational (animal model /spontaneous animal / human cancer treatment) setting. While my formal training is in veterinary pathology and radiation biology, I have used this expertise to develop and use animal models in many translational imaging and therapy research venues. I have spent very significant time using MRI, CT, ultrasound, PET, fluoroscopy and fluorescence imaging on large and small animal models and co-registering the findings with whole organ and histopathological specimens. I have been continually funded by the NIH and numerous corporate ventures for my entire research career. My position as Director of the Dartmouth Center for Comparative Medicine, Director of the Surgical Research Laboratories and co-Director (with Dr. Keith Paulsen) of the new Norris Cotton Cancer Center based small and large animal Imaging Shared Resource enhances my contact with investigators who use, desire to use advanced imaging techniques. I believe and hope that our ability to combine highly experienced large animal medical imaging and clinical expertise with the innovative and novel Advanced Imaging Center (small animals, large animal and clinical imaging including a intraoperative MRI-CT imaging facility now being built for large animals and human patients) in a personal manner is of benefit Dartmouth investigators. **Teaching and Mentoring:** I teach two courses yearly : “Introduction to Biomedical Engineering” (undergraduate course, Thayer School of Engineering) and “Quantitative Pathology for Biomedical Engineers”. Four of my five PhD graduate students are biomedical engineering or MD/PhD students who will be pursuing careers in medicine or biomedicine. I have mentored for more than 50 surgery residents who spent one or two years performing translational research (almost always animal model associated). **Research:** My current laboratory research focuses on “antibody and non-antibody directed iron oxide nanoparticle (magnetic NP) hyperthermia cancer treatment” (NCI-NIH Cancer Center for Nanotechnology Excellence award), but also involves several other hyperthermia based techniques including cornea reshaping, thermal ramifications spinal cord injury and treatment I am also the PI or co-PI of seven additional ongoing preclinical studies.

V. Councilor Candidates – Engineering & Physical Sciences



Dr. John C. Bischof, PhD
University of Minnesota
Dept of Mechanical Engineering
Minneapolis, MN

Current Research Interests:

The bioheat and mass transfer laboratory (BHMT) at the University of Minnesota is dedicated to the study of thermophysical and biological changes within biomaterials after thermal manipulations. This work is broadly in the scientific fields of thermal biology including cryobiology and hyperthermic biology, with particular focus in the following application areas: Nanomedicine, Thermal Therapies, Cryo and Biopreservation and Thermal/Mechanical Properties.

Education:

Ph.D. 1992, Mechanical Engineering, University of California, Berkeley
M.S. 1989, Biomedical Engineering, University of California, Berkeley and San Francisco (Joint Program)
B.S. 1987 Biomedical Engineering, University of California, Berkeley

Vision Statement: - There are an increasing number of focal thermal therapy devices and procedures that are used clinically for patients that are either poor surgical candidates or require options other than traditional chemotherapy and/or radiation therapy. These approaches are now used in almost every surgical subspecialty and include cancer,

cardiovascular and neural disease targets. This leads to an increased need to disseminate the underlying biology, engineering and clinical knowledge base in focal thermal therapies to yield optimal new device design, development and use. If elected as a councilor I would work to make sure that the state of the art in thermal therapy device design and use is represented at the STM meetings and in the Int. J. of Hyperthermia journal.

Current Work Position:

Professor, Department of Mechanical Engineering, University of Minnesota, Masonic Cancer Center



Dr. R. Jason Stafford, PhD
UT MD Anderson Cancer Center
Dept of Imaging Physics
Houston, Texas

Current Research Interests:

Thermal Ablation; Laser Ablation; Magnetic Resonance Temperature Imaging; MR-guided Interventions

Education:

UT Health Science Center at Houston and MD Anderson Cancer Center, PhD, Medical Physics

Vision Statement:

Thermal therapies as non- or minimally invasive approaches to the management and treatment of disease continue to be an area of rapid growth and research. In the last decade, advances in hyperthermia have been complimented by an explosive growth in high-temperature and cryoablation applications as well as a growing interest in the field of hypothermia. Synergistic with the emergence of these modalities are advancements in micro- and nanoparticle fabrication as well as thermally sensitive drugs which have the potential to facilitate increased specificity and efficacy of treatment delivery.

I strongly believe that, out of the many societies out there, the Society of Thermal Medicine and its journal, The International Journal of Hyperthermia, is in the unique position of cultivating a truly diverse, multi-disciplinary membership in which synergistic feedback between specialists working in the biology, chemistry, physics, engineering, clinical translation and regulatory aspects of thermal medicine can truly move the field forward and coherently address outstanding problems. From the engineering and physics perspective, this feedback is extremely important in the development of treatment modalities and protocols, innovative monitoring and thermometry techniques and the integration of high-performance computer modeling and simulation of therapy for treatment planning and online control. As these modalities mature, a great deal of deliberation must be spent on establishing standards and methods for quality control in order to progress from single institution to multi-institutional clinical trials. This is no easy task, but is an extremely appropriate task for a multidisciplinary society such as STM.

In addition to these roles of the society, I also see a potential fusion of expertise with other societies and regulatory groups as interest in the biological effects of heat, and how to measure, simulate and control it, mature. In addition to issues directly related to therapeutic use, interest is rising as old modalities (such as ultrasound and MRI) seek to establish their regulatory safety limits or emerging modalities look toward safe clinical translation.

In summary, I feel the importance of both the society and journal are increasing. As stewards of the society, it is our duty to embrace the changes, challenges and opportunities that face the field as well as to maintain focus on the primary mission of pioneering the field of thermal medicine in order to significantly improve patient outcomes. I hope to see the impact of the society grow through the outstanding science of our

members as presented at annual meetings and in the journal, as well as through targeted workshops and published proceedings in conjunction with sister societies which focus on much more specific clinical and research problems of interest to our membership. My hope is that, in this manner, STM will continue to grow as a premier society for scientists and clinicians working in the area of thermal medicine.

Current Work Position:

Associate Professor, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center